ARVINAS, INC. cotiza a 6.84 USD y tiene una capitalización bursátil de $441M. En los últimos 12 meses ha facturado $317M con un margen de flujo de caja libre del -105.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein dispos…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.58 | $-0.90 | $-1.10 |
| Estimado | $-0.95 | $-0.28 | $-0.96 | $-0.57 |
| Sorpresa | — | +1021.4% | +6.2% | -93.0% |
| Métrica | ARVN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -45.1% | -38.6% | -6.5% |
| Net Margin | -30.8% | -33.6% | +2.8% |
| FCF Margin | -105.0% | -13.9% | -91.1% |
| ROE | -18.6% | -40.4% | +21.8% |
| ROA | -11.3% | -32.0% | +20.8% |
| Current Ratio | 4.92 | 2.84 | +2.08 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |